Y-mAbs Therapeutics Inc expected to post a loss of 46 cents a share - Earnings Preview

Y-mAbs Therapeutics

17/03/2023 20:59

* Y-mAbs Therapeutics Inc  YMAB.OQ   YMAB.O  is expected
to show a
rise in quarterly revenue when it reports  results on March 17
(estimated). 
    * The New York City-based  company is expected to report  a
109.0% increase in revenue to $20.063 million from $9.6 million
a year ago, according to the mean estimate from 7 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Y-mAbs Therapeutics
Inc
is for a loss of 46 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 3
"hold" and 2 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Y-mAbs
Therapeutics Inc is $9​, above​ its last closing price of $3.28.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.71       -0.71      -0.63     Beat    11.3
 Jun. 30 2022  -0.67       -0.67      -0.94     Missed  -41.2
 Mar. 31 2022  -0.73       -0.72      -0.64     Beat    10.7​
 Dec. 31 2021  -0.70       -0.70      -0.85     Missed  -20.7
 ​​Sep.        -0.56       -0.60      -0.66     Missed  -10.4
 30 2021                                                
 Jun. 30 2021  -0.66       -0.67      -0.53     Beat    20.4​
 Mar. 31 2021  0.39        0.19       -0.68     Missed  -457.9
 Dec. 31 2020  -0.52       -0.51      -0.48     Beat    5.3
 This summary was machine generated March 17 at 20:59 GMT.  All
figures in US dollars  unless otherwise stated